We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 05, 2020

Consolidation Pembrolizumab Following Concurrent Chemoradiation for Unresectable Stage III NSCLC



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase 2 Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14-179
Cancer 2020 Jul 22;[EPub Ahead of Print], GA Durm, SK Jabbour, SK Althouse, Z Liu, AA Sadiq, RT Zon, SI Jalal, GH Kloecker, MJ Williamson, KL Reckamp, RM Langdon, EA Kio, RD Gentzler, BA Adesunloye, WA Harb, RV Walling, ML Titzer, NH Hanna

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading